Compare · CGEM vs GILD
CGEM vs GILD
Side-by-side comparison of Cullinan Therapeutics Inc. (CGEM) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGEM and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.19B, about 144.7x CGEM ($1.11B).
- Over the past year, CGEM is up 129.8% and GILD is up 15.7% - CGEM leads by 114.0 points.
- GILD has been more active in the news (5 items in the past 4 weeks vs 3 for CGEM).
- GILD has more recent analyst coverage (25 ratings vs 10 for CGEM).
- Company
- Cullinan Therapeutics Inc.
- Gilead Sciences Inc.
- Price
- $18.11-1.39%
- $129.81-3.72%
- Market cap
- $1.11B
- $161.19B
- 1M return
- +37.58%
- +3.47%
- 1Y return
- +129.76%
- +15.75%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 3
- 5
- Recent ratings
- 10
- 25
Cullinan Therapeutics Inc.
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest CGEM
- Chief Scientific Officer Michaelson Jennifer exercised 4,000 shares at a strike of $4.30 and sold $142,560 worth of shares (8,000 units at $17.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 162,844 units (SEC Form 4)
- Chief Legal Officer Sumer Jacquelyn L was granted 2,470 shares, increasing direct ownership by 2% to 130,559 units (SEC Form 4)
- Chief Financial Officer Fenton Mary Kay was granted 1,541 shares, increasing direct ownership by 1% to 127,921 units (SEC Form 4)
- SEC Form 4 filed by Director Rosenberg Anthony
- SEC Form 4 filed by Director Allen Andrew R
- SEC Form 4 filed by Director Webster Stephen W
- SEC Form 4 filed by Director Meek David D.
- SEC Form 4 filed by Director Doyle Mittie
- SEC Form 4 filed by Director Thistle Mary
- Cullinan Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest GILD
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)